CN1822860B - 偶联生物分子及其制备 - Google Patents

偶联生物分子及其制备 Download PDF

Info

Publication number
CN1822860B
CN1822860B CN2004800198144A CN200480019814A CN1822860B CN 1822860 B CN1822860 B CN 1822860B CN 2004800198144 A CN2004800198144 A CN 2004800198144A CN 200480019814 A CN200480019814 A CN 200480019814A CN 1822860 B CN1822860 B CN 1822860B
Authority
CN
China
Prior art keywords
group
polymer
compound
general formula
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800198144A
Other languages
English (en)
Chinese (zh)
Other versions
CN1822860A (zh
Inventor
安东尼·罗伯特·戈德温
埃莉萨·佩多内
崔志元
苏尼尔·肖纳克
斯蒂芬·詹姆斯·布罗基尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena (UK) Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27742023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1822860(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of CN1822860A publication Critical patent/CN1822860A/zh
Application granted granted Critical
Publication of CN1822860B publication Critical patent/CN1822860B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00—Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2004800198144A 2003-07-11 2004-07-12 偶联生物分子及其制备 Expired - Lifetime CN1822860B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation
GB0316294.8 2003-07-11
PCT/GB2004/002994 WO2005007197A2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010101399434A Division CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Publications (2)

Publication Number Publication Date
CN1822860A CN1822860A (zh) 2006-08-23
CN1822860B true CN1822860B (zh) 2010-05-05

Family

ID=27742023

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2004800198144A Expired - Lifetime CN1822860B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
CN2010101399434A Expired - Lifetime CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010101399434A Expired - Lifetime CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备

Country Status (13)

Country Link
US (4) US7595292B2 (enExample)
EP (4) EP2277550B1 (enExample)
JP (2) JP4958549B2 (enExample)
KR (1) KR101152500B1 (enExample)
CN (2) CN1822860B (enExample)
AT (1) ATE440620T1 (enExample)
AU (2) AU2004257448B2 (enExample)
DE (1) DE602004022824D1 (enExample)
DK (4) DK2133099T3 (enExample)
ES (4) ES2632515T3 (enExample)
GB (1) GB0316294D0 (enExample)
PL (2) PL2253330T3 (enExample)
WO (1) WO2005007197A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
TWI360535B (en) * 2007-08-30 2012-03-21 Univ Nat Sun Yat Sen Sulfur-containing compound, method of preparation
US20100239517A1 (en) * 2007-10-09 2010-09-23 Stephen Brocchini Novel conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
RU2582244C2 (ru) 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
ES2560807T3 (es) * 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
GB0817978D0 (en) * 2008-10-01 2008-11-05 Imp Innovations Ltd Peptides
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
FI124016B (fi) * 2009-10-26 2014-01-31 Vapo Oy Menetelmä biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi välipiirinesteen avulla sekä vesi-glykoliseoksen tai sitä vastaavan jäätymättömän välipiirinesteen käyttö biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi
KR20120103606A (ko) * 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
HK1200695A1 (en) 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
BR112014031613A2 (pt) * 2012-06-19 2017-07-25 Polytherics Ltd processo para preparação de conjugados de anticorpos e conjugados de anticorpos
NO2789793T3 (enExample) 2012-10-24 2018-01-27
ES2623209T3 (es) 2012-10-24 2017-07-10 Polytherics Limited Conjugados fármaco-proteína
AU2013350802B2 (en) * 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
EP3046588B1 (en) 2013-09-17 2022-03-02 OBI Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
ES2729643T3 (es) * 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
JP6721572B2 (ja) 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
HK1249528A1 (zh) * 2015-02-05 2018-11-02 Ablynx N.V. 通过c-末端合成半胱氨酸连接的纳米抗体二聚体
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCANARRAYS AND METHOD OF USE
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109152845B (zh) 2016-04-14 2022-07-12 宝力泰锐克斯有限公司 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
CN117534764A (zh) 2016-06-06 2024-02-09 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
KR20250049568A (ko) 2022-07-15 2025-04-11 페온 테라퓨틱스 리미티드 Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도
CN115304524A (zh) * 2022-07-21 2022-11-08 湖南大学 一种β-酰基烯丙基甲基砜类化合物及其高效合成方法
JP2025537044A (ja) 2022-09-30 2025-11-13 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ベンザゼピン誘導体、それを含む複合体およびその応用
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302209A (zh) * 1998-04-28 2001-07-04 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US20010011115A1 (en) * 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US680343A (en) * 1899-04-15 1901-08-13 Johan Peter Moeller Glove.
US3828412A (en) * 1971-03-19 1974-08-13 Dunham Bush Inc Method of forming high integrity epoxy joint between aluminum tubes
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0298101A1 (en) 1987-01-15 1989-01-11 Celltech Limited Thiol-reactive cross-linking reagents
ATE300519T1 (de) 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1995025764A1 (en) * 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Double-stranded derivative of polyoxyethylene-containing lipid
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
GB9713979D0 (en) 1997-07-03 1997-09-10 Univ Nottingham Method for attaching peg to macromolecules
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
JP2003528939A (ja) 1999-09-03 2003-09-30 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 分解性ポリマー
US6828412B1 (en) 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
JP4883515B2 (ja) 1999-09-08 2012-02-22 ポリセリックス リミテッド 均一分子量ポリマー
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) 2004-01-07 2004-02-11 Polytherics Ltd Complexes
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
US20100239517A1 (en) 2007-10-09 2010-09-23 Stephen Brocchini Novel conjugated proteins and peptides
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010011115A1 (en) * 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
CN1302209A (zh) * 1998-04-28 2001-07-04 应用研究系统Ars股份公司 多元醇干扰素β偶联物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BROCCHINI ET AL.Molecular yardsticks.Synthesis of extended equilibriumtransfer alkylating cross-link reagents and their useintheformation of macrocycles.JOURNAL OR THE AMERICAN CHEMICAL SOCIETY110 15.1988,110(15),Scheme I,Scheme II,化合物12-17,32.
BROCCHINI ET AL.Molecular yardsticks.Synthesis of extended equilibriumtransfer alkylating cross-link reagents and their useintheformation of macrocycles.JOURNAL OR THE AMERICAN CHEMICAL SOCIETY110 15.1988,110(15),Scheme I,Scheme II,化合物12-17,32. *
DEL ROSARIO R B ET AL.SULFHYDRYL SITE-SPECIFIC CROSS-LINKINGANDLABELING OF MONOCLONAL ANTIBODIESBYAFLUORESCENTEQUILIBRIUMTRANSFERALKYLATIONCROSS-LINKREAGENT.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),图1，schemeI.
DEL ROSARIO R B ET AL.SULFHYDRYL SITE-SPECIFIC CROSS-LINKINGANDLABELING OF MONOCLONAL ANTIBODIESBYAFLUORESCENTEQUILIBRIUMTRANSFERALKYLATIONCROSS-LINKREAGENT.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),图1,schemeI. *
LIBERATORE F A ET AL.SITE-DIRECTED CHEMICAL MODIFICATION ANDCROSS-LINKING OF A MONOCLONALANTIBODYUSINGEQUILIBRIUM TRANSFERALKYLATINGCROSS-LINKREAGENTS.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),scheme II,化合物12-15,scheme III.
LIBERATORE F A ET AL.SITE-DIRECTED CHEMICAL MODIFICATION ANDCROSS-LINKING OF A MONOCLONALANTIBODYUSINGEQUILIBRIUM TRANSFERALKYLATINGCROSS-LINKREAGENTS.BIOCONJUGATE CHEMISTRY1 1.1990,1(1),scheme II,化合物12-15,scheme III. *
ROBERTS M J ET AL.Chemistry for peptide and protein PEGylation.ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL54 4.2002,54(4),图1，图6，图14（2）.
ROBERTS M J ET AL.Chemistry for peptide and protein PEGylation.ADVANCED DRUG DELIVERY REVIEWS,AMSTERDAM,NL54 4.2002,54(4),图1,图6,图14(2). *
WILBUR D SCOTT ET AL."Monoclonal antibody Fab＇ fragment cross-linking using equilibrium transfer alkylation reagents. A strategyforsite-specific conjugation of diagnostic and therapeuticagentswith F(ab＇)2 -2 fragments".BIOCONJUGATE CHEMISTRY5 3.1994,5(3),图2，图1和第234页第3自然段.
WILBUR D SCOTT ET AL."Monoclonal antibody Fab'fragment cross-linking using equilibrium transfer alkylation reagents.A strategyforsite-specific conjugation of diagnostic and therapeuticagentswith F(ab')2-2 fragments".BIOCONJUGATE CHEMISTRY5 3.1994,5(3),图2，图1和第234页第3自然段. *

Also Published As

Publication number Publication date
ES2632515T3 (es) 2017-09-13
US20140369960A1 (en) 2014-12-18
EP1648518A2 (en) 2006-04-26
KR20060054286A (ko) 2006-05-22
WO2005007197A3 (en) 2005-03-31
JP5349552B2 (ja) 2013-11-20
ES2542531T3 (es) 2015-08-06
PL1648518T3 (pl) 2010-02-26
ES2331004T3 (es) 2009-12-18
AU2010257308A1 (en) 2011-01-13
JP2007527382A (ja) 2007-09-27
EP2133099A3 (en) 2010-03-10
DK2253330T3 (en) 2015-10-19
WO2005007197A2 (en) 2005-01-27
US20110182855A1 (en) 2011-07-28
DK2133099T3 (en) 2017-07-31
EP2253330A3 (en) 2011-03-09
CN101792525B (zh) 2012-06-06
AU2004257448A1 (en) 2005-01-27
EP2133099B1 (en) 2017-04-19
CN1822860A (zh) 2006-08-23
EP2253330A2 (en) 2010-11-24
US9439974B2 (en) 2016-09-13
DK1648518T3 (da) 2009-11-09
US8816051B2 (en) 2014-08-26
GB0316294D0 (en) 2003-08-13
ATE440620T1 (de) 2009-09-15
AU2010257308B2 (en) 2012-01-12
US20090298154A1 (en) 2009-12-03
EP2277550B1 (en) 2015-04-29
CN101792525A (zh) 2010-08-04
EP1648518B1 (en) 2009-08-26
US7595292B2 (en) 2009-09-29
DE602004022824D1 (de) 2009-10-08
EP2133099A2 (en) 2009-12-16
DK2277550T3 (en) 2015-08-03
ES2549427T3 (es) 2015-10-28
JP4958549B2 (ja) 2012-06-20
US20060210526A1 (en) 2006-09-21
AU2004257448B2 (en) 2010-09-23
EP2253330B1 (en) 2015-08-19
EP2277550A1 (en) 2011-01-26
PL2253330T3 (pl) 2016-01-29
KR101152500B1 (ko) 2012-07-05
US7939630B2 (en) 2011-05-10
JP2012021003A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
CN101792525B (zh) 偶联生物分子及其制备
CN101820920B (zh) 新的缀合蛋白质和肽
AU2013279079B2 (en) Conjugation reagents
US10174125B2 (en) Conjugation reagents
EP2403538A1 (en) Conjugated proteins and peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100505